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Abstract
Purpose: To evaluate AngioJet-assisted transvenous portal vein (PV) thrombectomy for non-cirrhotic patients with 
total portal vein and mesenteric vein thrombosis (PVMVT).
Material and methods: From 2015 to 2016 four patients (3 male, mean 43.9 years, range 33-52 years) with acute  
(3 cases) and acute-on-chronic (1 case) PVMVT underwent transvenous thrombolysis. All patients received initial 
AngioJet (Boston Scientific, Natick, MA, USA) thrombectomy followed by continuous catheter directed thrombolysis 
with Urokinase (Medac, Wedel, Germany) for 22-52 hours. Transjugular intrahepatic portosystemic shunts (TIPS), 
using Viatorr stent grafts (W.L. Gore and Associates, AZ, USA; mean diameter: 10 mm, length: 60-80 mm), were 
implanted in all patients. Patients were followed clinically and with imaging (mean 646 days, range 392 to 936 days).
Results: Technical success was 100%. Therapeutic success was achieved in 75% of cases. AngioJet-assisted thrombecto-
my substantially reduced thrombus load in the acute cases, while only slight improvement was achieved in the acute-
on-chronic case. Continuous thrombolysis subtotally re-established PV flow in the acute cases, while only minimal 
improvement was seen in the acute-on-chronic case. Following TIPS implantation complete PV recanalisation could 
be achieved in all acute cases. In the acute-on-chronic case initial stagnant PV flow was seen; however, PV and TIPS 
re-occluded 10 days after implantation. During follow-up PV remained patent in acute cases.
Conclusions: AngioJet-assisted thrombectomy was technically feasible and uncomplicated in all of our patients. The initial 
results suggest that AngioJet-assisted thrombectomy facilitates recanalisation in acute and severe cases of PVMVT.
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Introduction
In the general population acute portal vein thrombosis 
(PVT) is a rare disease [1]; however, among patients with 
cirrhosis its prevalence is as high as 15% [2], accompa-
nied by significantly increased mortality rates [3]. In non- 
cirrhotic patients PVT is infrequent and commonly caused 
by myeloproliferative diseases or congenital coagulopa-
thies. Nevertheless, non-cirrhosis-associated PVT is of 
growing interest; it is linked with increased morbidity and 
markedly shortened life expectancy in a commonly young 
and typically otherwise healthy patient collective [4].
Intestinal infarction with perforation and peritonitis are 
the most troubling immediate complications of PVT, with 
a related mortality rate of up to 60%. Thus, severe PVT is 
a medical emergency and necessitates rapid therapy. Suc-
cessful recanalisation of acute PVT following anticoagula-
tive monotherapy can be achieved in 38% of acute cases, 
while success is less probable in chronic and severe cases 
of PVT [5,6]. Endovascular, catheter-directed thrombolytic 
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therapy is an effective therapeutic option, supported by pre-
viously conducted studies reporting good results [7,8] and 
has now been adopted in the guidelines for treatment of 
PVT [9]. In theory portal vein (PV) thrombectomy allows 
for more rapid recanalisation of the PV. 
Although several endovascular devices have been sug-
gested for device-assisted PV-thrombectomy [10-13], data 
regarding the efficacy of this procedure are still sparse. We 
sought to investigate the efficacy of the AngioJet (Boston 
Scientific, Natick, MA, USA) for the treatment of massive 
portal vein and mesenteric vein thrombosis (PVMT). We 
present four cases of acute and acute-on-chronic PVMT 
in which restoration of PV patency was attempted by 
transjugular, transhepatic, AngioJet-assisted mechanical 
thrombectomy followed by establishment of TIPS.
Material and methods
Four patients (one female, mean age 43.9 years, range 33-
52 years) with, respectively, acute, acute-on-chronic portal 
vein, and mesenteric vein thrombosis (PVMVT) under-
went transvenous PV thrombectomy between 2015 and 
2016, in order to re-establish PV patency. 
All patients were surveyed clinically or by telephone 
follow-up and with imaging (mean 646, range 392 days 
to 936 days). None of the patients had a history of liver 
cirrhosis. 
All patients gave their written consent that clinical 
history, image material, and laboratory results could be 
used for scientific purposes. This study was carried out in 
accordance with the International Ethical Guidelines and 
the Declaration of Helsinki.
Technical success was defined as uncomplicat-
ed transjugular-transhepatic access to the PV system 
combined with uncomplicated implementation of the 
Angio Jet device for thrombectomy. Therapeutic success 
was defined as recanalisation of the PV, splenic vein, su-
perior mesenteric vein (SMV), and inferior mesenteric 
vein (IMV) with re-established hepatopetal flow fol-
lowing transvenous-transhepatic AngioJet-assisted PV 
Figure 1. Computed tomography (CT) images acquired in portal venous phase of a 33-year-old male – case 1 (A), 47-year-old male – case 2 (B), 
and a 44-year-old male – case 3 (C) show acute and extensive portal venous thrombosis. CT images of a 52-year-old female – case 4 (D) – show acute-





 Thrombectomy in the portal vein
e621© Pol J Radiol 2018; 83: e619-e627




A 33-year-old male presented with a seven-day his-
tory of progressive epigastric pain as well as new onset, 
slightly bloody diarrhoea. The patient had no history of 
bloody stools or similar abdominal pain in the past. Phys-
ical examination revealed severe abdominal tenderness 
and decreased bowel activity. The patient was haemody-
namically stable. Initial laboratory study revealed elevated 
C reactive protein (CRP) of 120 mg/l [normal range: 
0-3 mg/l]. Lactate was not increased with 1.10 mmol/l. 
Bilirubin (1.98 mg/dl) [normal range: 0.1-1 mg/dl], al-
kaline phosphatase (141 U/l) [normal range: 34-117 U/l] 
and aminotransferase (ALT 58 U/l) [normal range: < 50 U/l] 
were slightly elevated. Otherwise laboratory results were 
within normal range.
Computed tomography (CT) (Figure 1A) revealed 
extensive PVMVT with complete thrombotic occlusion 
of the intrahepatic PV. The extrahepatic PV (> 4 cm), 
the splenic vein (3.3 cm), the SMV (4.6 cm), and the IMV 
(3.6 cm) showed subtotal thrombotic occlusion extending 
into the pelvis and were markedly distended. Intestinal 
wall swelling of the small bowel was evident without signs 
of pneumatosis intestinalis. 
Case 2
A 47-year-old male with a history of recurring deep 
vein thrombosis for which the patient had received war-
farin for six months; otherwise the patient had no signifi-
cant past medical history. Initial laboratory study revealed 
an increased level of inflammatory indicators (leukocytes 
11.4 G/l, CRP 27.2 mg/l) and a slightly elevated ami-
notransferase (ALT 61 U/l); lactate was not increased, at 
1.20 mmol/l. Otherwise laboratory results were inconspic-
uous. 
The CT study (Figure 1B) revealed extensive PVMVT 
with complete thrombotic occlusion of the intrahepatic 
PV, and total thrombotic occlusion of the extrahepatic 
PV, the splenic vein, the SMV, and the IMV. Additionally, 
a mosaic pattern of hepatic perfusion was noted. The ex-
trahepatic PV (2 cm) and the SMV (1.8 cm) were margin-
ally dilated. CT showed no signs of intestinal ischaemia.
Case 3
A 44-year-old male with known protein-S deficien-
cy and history of deep vein thrombosis. The patient had 
stopped taking his prescribed Rivaroxaban due to re-
current haemorrhoidal bleeding. The patient presented 
with progressive abdominal tenderness. Initial laboratory 
findings showed an increased level of inflammation (CRP 
54.4 mg/l). Lactate was not increased, at 1.1 mmol/l. 
Alkaline phosphatase (122 U/l) and aminotransferase 
(ALT 57 U/l) were slightly elevated. Otherwise laboratory 
results were inconspicuous.
CT (Figure 1C) demonstrated total occlusion of the 
main PV, the splenic vein, the SMV, and IMV, while in-
trahepatic portal veins were mainly patent. Additionally, 
mesenteric stranding could be seen, especially surround-
ing the jejunum. Otherwise no signs of intestinal ischae-
mia were evident.
Case 4
A 52-year-old female with a known history of recur-
rent pancreatitis and partial PV thrombosis, who present-
ed with acute abdominal pain and signs of ileus. Initial 
laboratory study revealed an increased level of inflamma-
tion (leukocytes 38.25 G/l, CRP 186.0 mg/l) and slightly 
elevated gamma GT (38 U/l) [normal range: > 55 U/l], 
lactate was not increased, at 1.30 mmol/l. Otherwise lab-
oratory results were inconspicuous. Ultrasound showed 
moderate amounts of ascites. Paracentesis revealed spon-
taneous bacterial peritonitis with 2068 granulocytes/μl, 
which was treated antibiotically. 
CT (Figure 1D) demonstrated total obstruction of 
the PV, as well as partial occlusion of the splenic vein, 
the SMV, and IMV, with large amounts of wall-adherent 
thrombotic material, which led to the diagnosis of an 
acute-on-chronic PV thrombosis. Also, signs of chronic 
pancreatitis without acute oedema, a 3.5 cm large pseu-
docyst, moderate amounts of ascites, as well as signs of 
paralytic ileus were diagnosed. 
Procedure
Because symptoms progressed despite anticoagulation 
(intravenous heparin, partial thromboplastin time – PTT 
in therapeutic range), all patients were referred to in-
terventional PV-thrombolysis/thrombectomy following 
interdisciplinary case discussion. All procedures were 
carried out following informed consent and detailed re-
view of previous imaging. The procedures were performed 
using aseptic techniques under local anaesthesia (1% lido-
caine), intravenous analgesia, and sedation (pethidine and 
midazolam).
After attaining ultrasound-guided jugular venous ac-
cess, a 10 F sheath (Terumo, Tokyo, Japan) was inserted. 
The right hepatic vein was catheterised with a 4F multi-
purpose catheter. The portal venous system was accessed 
transhepatically under ultrasound guidance with the use of 
16G transjugular liver access and biopsy needle set (Cook, 
Bjaeverskov, Denmark). A hydrophilic-coated guidewire 
and a 4F multipurpose catheter were then manipulated 
through the occluded portal vein into the SMV. Direct 
portography was performed to document the extent of 
Daniel Kuetting, Karsten Wolter, Julian Luetkens et al.  
e622 © Pol J Radiol 2018; 83: e619-e627
the thrombotic occlusion (Figures 2-4). The guidewire was 
then exchanged for a PTFE-covered, stiff guidewire with 
a stainless-steel core (Amplatz, Cook, Bjaeverskov, Den-
Figure 2. Case 1. A) Initial portography after establishing transvenous 
portal vein access showing complete thrombosis of the portal vein without 
attention of intrahepatic portal veins. B) Portography after AngioJet-assisted 
thrombectomy and 46 hours of catheter-directed thrombolysis therapy, 
showing residual amounts of thrombus in the superior mesenteric vein and 
the main portal trunk. C) Portography following establishment of trans-
jugular intrahepatic portosystemic shunts showing complete recanalisation 




Figure 3. Case 2. A) Initial portography after establishing transvenous por-
tal vein access showing distension and complete thrombosis of the main 
portal vein and lacking attention of splenic vein as well as the intrahepatic 
portal veins. B) Portography after AngioJet-assisted thrombectomy and 
22 hours of catheter-directed thrombolysis therapy showing subtotal reso-
lution of portal vein and mesenteric vein thrombosis but residual intra-
hepatic portal vein (PV) thrombus. C) Portography following establishment 
of transjugular intrahepatic portosystemic shunts  showing complete recan-




mark). The short 10 F sheath was removed in exchange 
for a long 10 F sheath (Check-Flo Performer Introducer, 
Cook, Bjaeverskov/Denmark) and advanced into the PV 
after pre-dilatation of the puncture tract with 6-8-mm 
balloons (Mustang, Boston Scientific, Natick, MA, USA). 
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Figure 4. Case 4. A) Initial portography after establishing transvenous portal vein access showing lacking attenuation of the intrahepatic portal veins 
and subtotal thrombosis of the main portal vein, the splenic vein, and the superior mesenteric vein. B) Portography after AngioJet-assisted thrombec-
tomy and 48 hours of catheter-directed thrombolysis therapy showing only minimally improved portal venous flow and persisting complete thrombosis 
of the intrahepatic portal veins. C) Portography following establishment of transjugular intrahepatic portosystemic shunts (TIPS) showing recanalisation of 
the main portal vein (PV) but lacking attenuation of the intrahepatic portal veins, the splenic vein, and the superior mesenteric vein. D) Repeat portography 





Using the spray function of the AngioJet thrombecto-
my device (Boston Scientific, Natick, MA, USA) the throm-
bus in the splenic vein, the inferior mesenteric vein, the 
supe rior mesenteric vein, and the main portal vein were 
pre-treated with 250,000 IU of Urokinase (Medac, Wedel, 
Germany) diluted in saline. After 15 minutes of dwell 
time allowing for initial thrombus dissolution, mechani-
cal thrombectomy was performed using the power-pulse 
spray technique. Large amounts of red thrombus could be 
harvested in cases 1-3, while only small amounts of mainly 
white thrombus could be harvested in case 4. 
In the first three cases control portography revealed se-
verely reduced thrombus load with persistent evidence of 
flow-limiting clot (Figures 2 and 3). In the fourth case, only 
a slight reduction of thrombus load was seen (Figure 4). 
Extravasation was not seen in any of the cases. Subsequent 
catheter-directed thrombolysis was performed in all cas-
es due to residual PV thrombosis. Multiple-side-hole in-
fusion catheters (Uni Fuse, Angiodynamics, NY, USA) 
were inserted into the SMV and/or splenic vein/IMV 
over which continuous, catheter-directed thrombolysis 
was applied for 22-52 hours with a high dose of uroki-
nase (100,000 IU/h). After restoring hepatopetal venous 
flow in cases 1-3 (Figures 2, 3) a transjugular intrahepatic 
portosystemic shunt (TIPS) was implanted to complete-
ly re-establish and preserve PV patency. In case 4 TIPS 
was implanted as a bailout solution because thrombolytic 
therapy as well as additional aspiration thrombectomy led 
to only minimal improvement of PV-flow (Figure 4).
In all cases polytetrafluoroethylene-covered stent-grafts 
(Viatorr; W.L. Gore and Associates, AZ, USA) were used. All 
stents grafts had a nominal diameter of 10 mm. Stent lengths 
were chosen according to the distance of the confluence of 
the hepatic veins to the site of PV access. The employed stent 
lengths were 60, 70, and 80 mm (Figures 2-4). Post-place-
ment stent-graft dilatation was not performed. Postinter-
ventional PTT-adapted heparinisation was continued in all 
cases for at least 24 hours (goal PTT 40-60 sec), followed by 
oral anticoagulation with vitamin K antagonists.
Results
Technical success was achieved in all four cases. Thera-
peutic success was achieved in three out of four in cases.
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Urokinase lysis therapy was performed until hepato-
petal flow was re-established in the PV, the splenic vein, 
the SMV, and the IMV. Lytic therapy was performed for 
46 (case 1), 22 (case 2), and 27 hours (case 3), leading to 
a total dose of 3,650,000 IU (case 1), 2,050,000 IU (case 2), 
 and 2,950,000 IU (case 3). 
Following the establishment of TIPS, complete recana-
lisation of the PV, the splenic vein, the SMV, and the IMV 
were documented by angiography and by sonography in 
cases 1-3 (Figures 2 and 3).
In case 4 PV thrombosis was almost completely refrac-
tory to the intervention and also to subsequent catheter-di-
rected continuous lysis. Because control angiography showed 
only minimal signs of improvement (Figure 4) thrombolytic 
therapy was stopped after 52 hours of continuous uro-
kinase administration (applied total dose: 5,200,000 IU). 
Following the establishment of TIPS, partial recanalisa-
tion of the main PV was achieved; however, PV flow re-
mained stagnant. The intrahepatic portal vein branches, 
the splenic vein, the SMV, and the IMV remained mainly 
occluded (Figure 4). 
Clinical symptoms
In cases 1 to 3 symptomatic relief of abdominal pain and 
or bloody diarrhoea was attained before discharge. In 
case 4 peritonitis and its complications (paralytic ileus) 
were successfully treated, and abdominal pain could be 
reduced, but it persisted until discharge.
Complications
Cases 1 and 2 developed temporary haematuria during 
thrombolytic therapy, which did not lead to bladder tam-
ponade, did not affect haemoglobin levels, and did not 
necessitate transfusion. Urokinase dosage was reduced to 
50,000 IU/h, and three-way Foley urinary catheters were 
introduced. Otherwise, no immediate complications were 
identified.
Screening
Thrombophilia screening was performed parallel to end-
ovascular thrombectomy/thrombolysis in all patients. 
In case 1 screening revealed no conspicuous findings. In 
cases 2 and 4 a JAK2-V617F-mutation, consistent with 
myeloproliferative syndrome, was diagnosed. In case 
3 a protein-S deficiency had been pre-diagnosed, and 
thrombophilia screening revealed no further abnormali-
ties. Shear-wave elastography revealed no signs of under-
lying liver cirrhosis in any of the cases. 
Follow up 
Case 1: During follow-up the patient presented with an 
episode of encephalopathy four months after TIPS im-
plantation, after having discontinued his laxatives a week 
before. Encephalopathy could be controlled medically. In 
following controls (total duration: 31 months) ultrasound 
revealed PV and TIPS patency with intrahepatic PV 
hepatopetal flow. Follow-up laboratory tests showed nor-
mal values of liver enzymes, and follow-up psychometric 
tests revealed no signs of reoccurrence of encephalopathy. 
Case 2: During follow-up controls (total duration: 
24 months) ultrasound revealed PV and TIPS patency 
with intrahepatic PV hepatopetal flow. Follow-up labora-
tory tests showed normal values of liver enzymes. Psycho-
metric tests revealed no signs of encephalopathy. 
Case 3: Ultrasound follow-up two months post inter-
vention showed that TIPS and PV were patent. MRI per-
formed three months post procedure, however, revealed 
TIPS occlusion with persistent PV patency. The reason 
for TIPS thrombosis remained unclear. Recanalisation 
was not attempted because PV remained patent, and the 
patient remained clinically stable. Further clinical controls 
(total duration nine months) with laboratory and ultra-
sound follow-up confirmed PV patency and showed nor-
mal values of liver enzymes. Psychometric tests revealed 
no signs of encephalopathy. The patient did not appear to 
further clinical examinations. During telephone follow-up 
performed 17 months post-procedure the patient report-
ed having neither abdominal symptoms nor subjectively 
noticeable cognitive impairment.
Case 4: Ultrasound performed 10 days after implan-
tation of TIPS revealed subtotal thrombotic TIPS occlu-
sion (Figure 4). The patient was referred to interventional 
radiology again to attempt TIPS- and PV-recanalisation. 
By means of aspiration thrombectomy and thrombolytic 
therapy, PV and TIPS were successfully recanalised; how-
ever, the TIPS re-occluded again 10 days later. Another 
attempt to re-establish PV patency was not undertaken.
Duplex sonography performed two months and 
12 months after intervention showed a complete occlusion 
of the TIPS tract and the splanchnic venous system with 
cavernous transformation of the portal vein. Gastroscopy 
revealed oesophageal varices I°, psychometric testing re-
vealed no signs of hepatic encephalopathy, and laboratory 
follow-up showed normal values of liver enzymes.
Discussion
The management of acute PVT in patients without cir-
rhosis or malignancy is complex and not yet sufficiently 
represented in national guidelines. Recently, however, the 
consensus paper of the Baveno VI conference [9] was re-
leased, on which the European guidelines of the European 
Association for the Study of the Liver (EASL) are based. 
The consensus paper includes revised treatment recom-
mendations of non-cirrhotic PVT: Initial therapy is iden-
tical to that of cirrhotic PVT, with immediate commence-
ment of low-molecular-weight heparin followed by oral 
anticoagulant therapy. In the case of persistent abdominal 
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pain, varicose haemorrhage, bloody diarrhoea, or lactic 
acidosis despite commencement of anticoagulative thera-
py [9], interventional revascularisation should be consid-
ered in non-cirrhotic PVT patients. The therapy of choice 
to achieve revascularisation, however, is not specified.
In this regard, several different interventional tech-
niques (systemic, indirect, and direct) have been pro-
posed to access and administer thrombolytic agents in the 
PV. Among these the direct approaches appear the most 
promising, with higher success rates in comparison to sys-
temic and indirect approaches [13]. Another advantage 
of the direct approach is the prospect of device-assisted 
thrombectomy/thrombolysis, which has been shown to 
expedite the procedure [11,12].
Although the duration of thrombolytic therapy in the 
current study was comparable to prior studies and case 
reports where only catheter directed pharmacological lysis 
was performed [14-16], the extent of PV and splanchnic 
thrombosis was more substantial in the current cases. We 
therefore believe that AngioJet-assisted thrombectomy 
expedited the procedure nonetheless.
Although randomised control trials regarding the ef-
ficacy of minimally invasive direct PV thrombolysis are 
still lacking, the published case reports and case series 
[10,16-18], now including over 150 patients, indicate prom-
ising results, with recanalisation rates as high as 80% [6].
Direct thrombolysis/thrombectomy of the PV is feasi-
ble via a percutaneous trans-splenic-, percutaneous tran-
shepatic, as well as a transvenous transhepatic approach. 
In a recently published case series including five patients 
the combination of the trans-splenic and the transhepatic 
approach showed good results (100% technical success 
rate) for treatment of chronic PVT [10]. However, the 
authors concede that there are potential complications 
of splenic capsular perforation and abdominal bleed-
ing. Similarly, the percutaneous transhepatic approach 
[8,11] also requires capsule perforation and is therefore 
associated with an elevated risk of complications (up to 
60% of patients show subcapsular hepatic haematoma 
or intra-abdominal bleeding) [8,16]. In comparison, the 
transvenous-transhepatic approach also allows for direct 
thrombolysis without obligatory organ capsule perfo-
ration and allows for post-lysis TIPS establishment to 
ensure PV patency [19]. Because the transvenous-tran-
shepatic approach (unlike the two above-mentioned tech-
niques) does not usually pass through the intraperitoneal 
cavity, it is also suitable for patients with existing ascites 
and coagulative dysfunction [15].
In theory, percutaneous mechanical thrombectomy/
thrombolysis devices can decrease the duration of lytic 
therapy and reduce the required amount of thrombolyt-
ic drugs. Several different devices have been successfully 
used for portal vein thrombectomy/thrombolysis; among 
these are the Trellis, the EKOS, and the AngioJet device. 
The Trellis device (Covidien, Bacchus Vascular, CA, 
USA), which is currently not commercially available, con-
sists of an oscillating nitinol wire between two balloons 
between which thrombolytic agents can be injected. In 
a case reported by Darcy an occluded TIPS and throm-
bosed PV could be recanalised with the Trellis device via 
a trans-jugular approach in combination with thromboly-
sis therapy in a single session [12]. The patient developed 
postinterventional diffuse alveolar haemorrhage, which 
necessitated intubation and bronchoscopy. In following 
ultrasound controls TIPS and PV remained patent.
The ultrasound-assisted EKOS Endowave device 
(EKOS Corporation, WA, USA) is a multiple side-hole 
infusion catheter, which additionally contains ultrasound 
transducers that emit low power sound waves. These 
sound waves cause fibrin strands to thin, thus expediting 
lysis. Abdel Aal et al. recently presented a case in which 
ultrasound-accelerated PV thrombolysis performed 
in a patient with acute, partial thrombosis via a trans- 
hepatic approach could severely reduce thrombus load af-
ter 30 hours of ultrasound-accelerated thrombolysis [11]. 
PV remained patent in the following controls, and no com-
plications associated with the intervention were noted.
The AngioJet device combines pharmacological and 
mechanical thrombectomy. In the first step a spray engine 
is used to disperse the lytic agent throughout the throm-
bus. After letting the lytic agent dwell for several minutes, 
the spray engine is combined with a high-pressure pump, 
which leads to an intra-vasal pressure gradient (Venturi 
effect), ultimately causing thrombus fragmentation and 
allowing aspiration of thrombus into the catheter. 
Although AngioJet-assisted transvenous-transhepatic 
portal venous thrombectomy followed by the creation of 
TIPS has been successfully used in previous case reports 
[20,21], to date it is not an established therapy option. 
The current results support that the AngioJet device can 
effectively reduce thrombus load in the setting of acute 
PVT. In three of our cases thrombus load could be signif-
icantly reduced, leading to a reduction of both the dura-
tion of the subsequent continuous thrombolytic therapy 
and the amount of applied thrombolytic agent.
In the fourth case of our series AngioJet therapy could 
only minimally reduce PV-thrombus load, and also con-
tinuous thrombolytic therapy showed no significant im-
provement of PV-flow. This patient had a known history 
of partial PV-thrombosis and probably presented with 
an acute-on-chronic PV thrombosis, highlighted by the 
fact that mechanical thrombectomy retracted mainly 
white thrombus and only small amounts of red thrombus 
from the PV. Even though endovascular approaches have 
been shown to enable successful recanalisation of chronic 
PV thrombosis [10], the transvenous-transhepatic ap-
proach using the AngioJet does not appear favourable for 
this intervention.
It is debatable whether mechanical thrombectomy 
should be performed initially or following primary con-
tinuous thrombolytic therapy. Both approaches offer ad-
vantages. We chose to initiate therapy with mechanical 
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thrombectomy. Removing thrombus load increases the 
surface of the remaining thrombus, consequently making 
thrombolytic therapy more effective. Performing initial 
continuous thrombolysis will possibly facilitate mechan-
ical thrombectomy; however, it may also significantly in-
crease the risk of haemorrhage during the intervention. 
Contrary to Haskal’s report [20], in which Angio-
Jet thrombectomy sufficed to recanalise a thrombosed 
PV, in the current cases continuous lysis had to be per-
formed following initial AngioJet-assisted thrombectomy. 
Although the extent of PV thrombosis was not specified in 
the case by Haskal, we presume that additional continuous 
lytic therapy was necessary in the current patient collective 
due to more severe PV thrombosis (thrombosis extending 
into the pelvis, markedly dilated PV and mesenteric veins). 
Following successful recanalisation of the PV, implan-
tation of TIPS should be discussed in cases with extensive 
PV thrombosis as well as residual clot following lytic ther-
apy. Once hepatopetal PV-flow is re-established, creation 
of a portosystemic shunt can increase splanchnic flow and 
thus generate a sufficient gradient to expedite residual clot 
dissolution and maintain PV patency, as could be seen in 
three of our four patients. Furthermore, TIPS decreases 
the risk of PV re-thrombosis [22]. In the fourth patient 
TIPS was implanted as a bailout solution in an attempt 
to improve PV-flow because lytic therapy had failed to 
re-establish hepatopetal flow. However, insufficient in-
flow may lead to occlusion/re-occlusion of PV and TIPS. 
Therefore, TIPS implantation should only be advocated in 
PV-thrombosis patients in whom hepatopetal PV flow has 
been re-established.
Concordant with the report of Haskal [20], TIPS was 
established only after having performed device-assisted 
PV-thrombectomy. Although this does not eliminate the 
risk of peri-interventional pulmonary embolisation (PE), 
it is markedly reduced nonetheless, further highlighted 
by the fact that PE was not clinically evident in any of the 
included patients nor reported in the case by Haskal.
Careful patient selection is essential because TIPS can 
lead to a deterioration of liver function and hepatic enceph-
alopathy [23], even in the absence of primary liver disease. 
Although PVT was previously considered a contraindica-
tion for TIPS [24], recent results from centres specialising 
in TIPS demonstrate that patients with severe acute and 
chronic PVT tend to profit from a portosystemic shunt 
[25-27]. Currently, data is still lacking regarding whether 
TIPS should be occluded or remain patent after successful 
PV recanalisation. In the current cases the interdisciplinary 
decision was made to not occlude TIPS due to the elevated 
risk of re-thrombosis in this patient collective. It is impor-
tant to note that not every patient with PVT requires the 
implantation of TIPS. However, TIPS has been shown to 
increase PV patency and decrease mortality in patients with 
severe PVT and life-threatening complications of portal 
vein thrombosis as well as congenital/acquired coagulopa-
thies with increased risk of re-thrombosis [28].
In our patient collective TIPS were implanted because 
of extensive PVT involving both the SMV and the IMV, 
and it was also indicated by prothrombotic predisposition 
in two of these. 
Follow-up and complete diagnostic work-up of PVT 
is just as important as acute treatment. 
Patients who do not show signs of cirrhosis or who 
present with compensated cirrhosis (Child A or B) should 
be thoroughly evaluated for conditions that may predis-
pose PVT. Thrombophilic conditions or other triggering 
factors can be identified in up to 75% of cases [29]. Di-
agnosing the underlying aetiological factor for PVT may 
have a therapeutic impact; for instance, the presence of 
prothrombotic disorders influences the duration of anti-
coagulant treatment in PVT – these have been shown to 
be independent predictors of recurrent thrombosis [30]. 
In our patient collective all patients, including the patient 
lacking a coagulopathy, received indefinite oral anticoag-
ulation with vitamin K antagonists, due to the extent of 
thrombosis and the risk of PV re-thrombosis.
There are limitations to our study that have to be dis-
cussed. We conducted this study retrospectively in a small 
patient collective, owing to the fact that PVT is a rather 
rare entity in non-cirrhotic patients. Nevertheless, the 
high rate of successful recanalisation combined with a low 
complication rate is promising.
In summary, the goal of therapy is a rapid recan-
alisation of the PV and SMV/IMV to prevent venous 
infarction and portal hypertension. In addition to first-
line therapy (anticoagulation), the device-assisted trans-
venous-transhepatic approach has been shown to be 
effective and safe with high rates of recanalisation. An-
gioJet-assisted thrombectomy was technically feasible and 
uncomplicated in all of our patients. The initial results 
suggest that AngioJet-assisted thrombectomy combined 
with thrombolysis enables recanalisation in acute and se-
vere cases of PVMVT. 
Conclusions
Transvenous transhepatic AngioJet-assisted recanalisation 
of acute portal vein thrombosis is a safe and effective ap-
proach. 
AngioJet-assisted thrombectomy appears not to be fa-
vourable in chronic portal vein thrombosis. 
Establishment of transjugular intra-hepatic stent shunt 
(TIPS) following PV recanalisation can help preserve PV 
patency.
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